FMR LLC trimmed its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 23.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,024,416 shares of the biopharmaceutical company's stock after selling 1,804,748 shares during the period. FMR LLC owned about 9.08% of Celldex Therapeutics worth $204,770,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. Novo Holdings A S increased its stake in shares of Celldex Therapeutics by 13.4% during the 3rd quarter. Novo Holdings A S now owns 963,663 shares of the biopharmaceutical company's stock worth $32,755,000 after purchasing an additional 113,663 shares in the last quarter. Jennison Associates LLC grew its stake in Celldex Therapeutics by 32.0% in the 3rd quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company's stock worth $45,017,000 after acquiring an additional 321,325 shares during the period. AlphaCentric Advisors LLC grew its stake in Celldex Therapeutics by 23.4% in the 2nd quarter. AlphaCentric Advisors LLC now owns 47,500 shares of the biopharmaceutical company's stock worth $1,758,000 after acquiring an additional 9,000 shares during the period. Point72 Asset Management L.P. grew its stake in Celldex Therapeutics by 51.0% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company's stock worth $71,725,000 after acquiring an additional 654,194 shares during the period. Finally, Bank of New York Mellon Corp grew its stake in Celldex Therapeutics by 14.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 230,162 shares of the biopharmaceutical company's stock worth $8,518,000 after acquiring an additional 29,324 shares during the period.
Celldex Therapeutics Stock Performance
CLDX stock traded down $0.84 during trading on Tuesday, reaching $26.39. The stock had a trading volume of 142,141 shares, compared to its average volume of 882,323. Celldex Therapeutics, Inc. has a 1-year low of $22.93 and a 1-year high of $53.18. The firm has a fifty day moving average price of $28.55 and a 200 day moving average price of $34.30.
Insider Activity
In related news, CEO Anthony S. Marucci bought 11,500 shares of the business's stock in a transaction dated Monday, November 11th. The shares were acquired at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the purchase, the chief executive officer now owns 40,284 shares in the company, valued at $1,080,416.88. This trade represents a 39.95 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 3.80% of the company's stock.
Wall Street Analysts Forecast Growth
CLDX has been the subject of several recent analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, November 20th. Cantor Fitzgerald reissued an "overweight" rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research note on Monday, September 16th. Citigroup initiated coverage on shares of Celldex Therapeutics in a research note on Monday, October 7th. They set a "buy" rating and a $70.00 price objective for the company. Wells Fargo & Company raised shares of Celldex Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Thursday, September 26th. Finally, The Goldman Sachs Group began coverage on shares of Celldex Therapeutics in a research note on Monday, September 30th. They set a "neutral" rating and a $45.00 price objective for the company. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $62.25.
Check Out Our Latest Stock Report on Celldex Therapeutics
About Celldex Therapeutics
(
Free Report)
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
Further Reading
Before you consider Celldex Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.
While Celldex Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
